KR20220119065A - 불면증 치료를 위한 렘보렉산트의 용도 - Google Patents

불면증 치료를 위한 렘보렉산트의 용도 Download PDF

Info

Publication number
KR20220119065A
KR20220119065A KR1020227023903A KR20227023903A KR20220119065A KR 20220119065 A KR20220119065 A KR 20220119065A KR 1020227023903 A KR1020227023903 A KR 1020227023903A KR 20227023903 A KR20227023903 A KR 20227023903A KR 20220119065 A KR20220119065 A KR 20220119065A
Authority
KR
South Korea
Prior art keywords
lemborexant
child
acceptable salt
patient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227023903A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 새틀린
마가렛 몰린
이샤니 랜드리
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20220119065A publication Critical patent/KR20220119065A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020227023903A 2019-12-20 2020-12-18 불면증 치료를 위한 렘보렉산트의 용도 Pending KR20220119065A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951638P 2019-12-20 2019-12-20
US62/951,638 2019-12-20
PCT/US2020/065891 WO2021127359A1 (en) 2019-12-20 2020-12-18 Use of lemborexant for treating insomnia

Publications (1)

Publication Number Publication Date
KR20220119065A true KR20220119065A (ko) 2022-08-26

Family

ID=74191874

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227023903A Pending KR20220119065A (ko) 2019-12-20 2020-12-18 불면증 치료를 위한 렘보렉산트의 용도

Country Status (11)

Country Link
US (1) US20230051268A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076463A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023508011A (cg-RX-API-DMAC7.html)
KR (1) KR20220119065A (cg-RX-API-DMAC7.html)
CN (1) CN115003305A (cg-RX-API-DMAC7.html)
AU (1) AU2020408557A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012246A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165481A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007304A (cg-RX-API-DMAC7.html)
TW (1) TW202137986A (cg-RX-API-DMAC7.html)
WO (1) WO2021127359A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260029363A (ko) * 2023-06-29 2026-03-04 얀센 파마슈티카 엔브이 셀토렉산트를 이용한 우울증 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
RU2571414C2 (ru) 2010-09-22 2015-12-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циклопропановые соединения
US9416109B2 (en) 2012-02-17 2016-08-16 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
JP6659681B2 (ja) * 2014-10-23 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法
KR20230170136A (ko) * 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법

Also Published As

Publication number Publication date
BR112022012246A2 (pt) 2022-08-30
CA3165481A1 (en) 2021-06-24
MX2022007304A (es) 2022-08-22
US20230051268A1 (en) 2023-02-16
EP4076463A1 (en) 2022-10-26
CN115003305A (zh) 2022-09-02
JP2023508011A (ja) 2023-02-28
WO2021127359A1 (en) 2021-06-24
AU2020408557A1 (en) 2022-08-11
TW202137986A (zh) 2021-10-16
JP2025160480A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
CA2829947C (en) Dosing regimens for the treatment of fabry disease
AU2012328388B2 (en) Treatment protocol of diabetes type 2
RU2703297C2 (ru) Композиции и способы для лечения бессонницы
KR102165434B1 (ko) 2형 당뇨병 및 다른 장애의 치료를 위한 glp1r 작용제 및 메트포민의 조합 및 이것들의 사용법
JP2015537009A (ja) 痛風の治療におけるブシラミンの使用
JP2024523945A (ja) 血糖値の管理方法ならびに糖尿病及び関連状態の治療
JP2025160480A (ja) 不眠症を治療するためのレンボレキサントの使用
AU2026201519A1 (en) Lemborexant for treating sleep issues
CN101584700A (zh) 一种药物组合物
CN106619624A (zh) 依帕司他在制备治疗高尿酸血症和痛风药物中的应用
US20160000738A1 (en) Use of bucillamine in the treatment of gout
CN104582701A (zh) 减轻体重的方法
JPH01261331A (ja) 急性及びアルコール中毒の治療に有用なフラクトース−1,6−二燐酸塩含有薬剤組成物
KR20230143978A (ko) 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
Roy Administration of once-daily canagliflozin to a non-diabetic patient in addition to standard aerobic exercise: a case report
EP2083817A2 (en) Method of restoring the incretin effect
WO2020211772A1 (en) Purmorphamine as a small compound positive allosteric modulator of secretin receptor for the treatment of hypertension
Aher et al. Linagliptin: A Review on Therapeutic Role in Diabetes Mellitus.
CA3011062A1 (en) Pharmaceutical formulations for the treatment of diabetes
Sharma Diabetes mellitus: an overview
Islam A review on synthesis, characterization, and pharmacological evaluation of second-line antidiabetic drugs
RU2304439C1 (ru) Лекарственное средство и способ лечения сахарного диабета
RU2844395C2 (ru) Лемборексант для лечения проблем со сном
WO2025189151A1 (en) Methods and compositions for treating disorders associated with low c-peptide
Patil et al. Pharmaceutical Interactions in Drug Practices

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000